Network analysis of drug-related problems in hospitalized patients with hematologic malignancies

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Myeong Gyu KimJung Mi Oh

Abstract

Network analysis was conducted to systematically analyze the relationship between causative drugs and types of drug-related problems (DRPs) in hospitalized patients with hematologic malignancies. A total of 1187 DRPs identified in hematology wards between 2013 and 2015 were analyzed. DRPs were classified into 11 sub-domains for problems and 35 sub-domains for causes according to Pharmaceutical Care Network Europe classification. Causative drugs were classified by Anatomical Therapeutic Chemical code. Network analytic tool was used to represent the relationship between drugs, causes, and problems. In-degree centrality (CD-in) was calculated to identify major causes of DRPs. The following drugs accounted for more than 5% of DRP, including antibacterials (J01, 26.5%), drugs for acid-related disorders (A02, 11.5%), antiemetics (A04, 9.7%), antifungals (J02, 8.8%), and antineoplastic agents (L01, 7.0%). Inappropriate combinations (C1.3, CD-in of 161) of drugs for acid-related disorders, antifungals, and antineoplastic agents were major causes of DRPs and induced non-optimal effects of drug treatment (P1.2). Inappropriate dose adjustments (C3.6, CD-in of 151) of antibacterials lowered effects (P1.2) and increased side effects (P2.1)....Continue Reading

References

Dec 14, 1999·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·J M Overhage, A Lukes
May 9, 2006·Critical Care : the Official Journal of the Critical Care Forum·Michael DarmonElie Azoulay
Sep 21, 2006·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Eva Rämme BrembergStaffan Eksborg
Dec 7, 2007·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·E Cavero RodrigoN V Jiménez Torres
Mar 25, 2008·Therapeutics and Clinical Risk Management·Yvonne KohShu Chuen Li
Sep 28, 2010·Lancet·Frank Pasqualone
Nov 28, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ting Ting YeohLita Chew
Jan 4, 2013·International Journal of Clinical Pharmacy·Arjan BulsinkFrank G A Jansman
Sep 26, 2013·Journal of Pharmacy Practice·Scott J EdwardsNeil J MacKinnon
Jan 31, 2014·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Cindy ChewTt Yeoh
Feb 22, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alexandre ChanJoen Chiang
Mar 19, 2014·Clinical Therapeutics·Yu KoAlexandre Chan
Oct 20, 2014·International Journal of Clinical Pharmacy·Carmen Lopez-MartinVicente Faus Felipe
Jun 20, 2015·Journal of Geriatric Oncology·Ting Ting YeohLita Chew
Dec 31, 2015·International Journal of Clinical Pharmacy·Almudena RibedMaria Sanjurjo-Sáez
Oct 21, 2016·Einstein·Tatiane Fernandes FariasJuliane Carlotto

❮ Previous
Next ❯

Citations

Dec 11, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yun-Kyoung Song, Jung Mi Oh
Apr 8, 2020·Journal of Oncology·Malede Berihun YismawEphrem Engidawork

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.